{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-020728","form_type":"8-K","ticker":"PCSA","cik":"0001533743","company_name":"Processa Pharmaceuticals, Inc.","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.434550+00:00","generated_at":"2026-05-15T00:45:08.196987+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Processa Pharmaceuticals transitions Chief Development Officer to part-time role effective May 1, 2026","bullets":["Dr. Sian Bigora moves from full-time executive to part-time employee, retains Chief Development and Regulatory Officer title.","She will no longer be an executive officer under Section 16 of the Exchange Act.","Existing employment agreement terminated; replaced by new part-time arrangement effective May 1, 2026.","Dr. Bigora retains all previously granted equity awards and remains eligible for prior bonus compensation.","Transition is part of her planned path toward retirement, as stated by the company."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-020728","json":"https://secwatch.observer/filing/0001493152-26-020728.json","markdown":"https://secwatch.observer/filing/0001493152-26-020728.md","text":"https://secwatch.observer/filing/0001493152-26-020728.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533743/000149315226020728/0001493152-26-020728-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533743/000149315226020728/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:45:08.196987+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"db628ce307","claim":"Sian Bigora changed role as Chief Development and Regulatory Officer at Processa Pharmaceuticals, Inc..","evidence_excerpt":"On April 30, 2026, Processa Pharmaceuticals, Inc. (the “Company”) approved a transition in the employment status of Dr. Sian Bigora, the Company’s Chief Development and Regulatory Officer, as part of her planned transition toward retirement.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533743/000149315226020728/0001493152-26-020728-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned from full-time executive officer to part-time employee"},{"label":"Role","value":"Chief Development and Regulatory Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}